IDO1 and familial pancreatic carcinoma: IDO2 has been reported to be overexpressed along with IDO1 in pancreatic cancer (22, 23), and in basal cell skin carcinomas, where its expression appears to be driven by the T-cell-attracting chemokine CXCL11 (16), but neither the extent of IDO2 expression nor knowledge of its regulatory mechanisms in cancer settings are as widely described as IDO1 as yet.